Ulipristal acetate does not impact human normal breast tissue

作者：Communal Laudine; Vilasco Myriam; Hugon Rodin Justine; Courtin Aurelie; Mourra Najat; Lahlou Najiba; Dumont Sylvie; Chaouat Marc; Forgez Patricia; Gompel Anne^*

来源：Human Reproduction, 2012, 27(9): 2785-2798.

DOI：10.1093/humrep/des221

• Ki67
• cyclin A
• BCL2
• FASN
• IEX-1

Antiprogestins are of growing interest for the development of new treatments in the gynecological field. Ulipristal acetate (UPA) is a progesterone receptor (PR) modulator considered for long-term administration in contraception and is currently being registered for the treatment of uterine fibroids. In light of the influences of hormonal dysfunction in breast pathologies, the secondary consequences of chronic UPA therapy need to be established. The aim of this study was to determine UPA actions mediated by PR and glucocorticoid receptor (GR) in normal and transformed breast. %26lt;br%26gt;UPA, progesterone (P) and dexamethasone (DEX) effects were observed on PR and GR responsive genes and on proliferation and apoptosis of normal human breast epithelial (HBE) and breast cancer cells. Human normal breast tissue samples were xenografted in athymic mice and treated with estradiol (E2), or E2 P, or E2 P UPA. %26lt;br%26gt;Analysis of PR and GR reporter gene transactivation and their respective endogenous target genes indicated that UPA exerted anti-progestational and anti-glucocorticoid activity in both types of cells with a more pronounced effect in cancer cells. When combined with P or DEX, UPA limits the proliferation of HBE cells but increases growth in breast cancer cell lines. UPA administration had no impact on the mitotic index on xenografted human breast tissue exposed to gonadal hormones at similar concentrations to those present in normal women. %26lt;br%26gt;Although further clinical trials are required to confirm that the results from our experimental models can be extrapolated to women treated with UPA, they suggest that such treatment would not be deleterious to normal breast tissue at least for a cycle (28 days) of continuous administration.

• 出版日期2012-9